They're certainly making it harder for J&J to come back. Strategically we believe Boston Scientific with Guidant is a better match.

Interestingly, (Boston Scientific) only raised its bid by $1, signaling that price is but one factor in the negotiation - but includes timeliness of closure.

We doubt this show is over, and in the end we expect that Boston Scientific will increase its bid.

There's a phrase: to strike while the iron is hot. The iron is hot.

In our opinion this news is not new and should not slow down the merger with Guidant.

The good news is that this is not a recall, products are not being removed from hospital shelves, and no one has died.